然而，随着全国离子交换法生产碳酸钾产能不断提升，氯化铵的处置，已上升为行业难题，同时，在国 家环保高压态势下，大批同行纷纷倒下......面对发展逆境，大洋人决定在夹缝中求生存、在逆境中寻契 机，艰难开辟出一条生产与环保同步发展的常态化创新之路——他们联合科研院所，投入2000万元，研 发出全国首套规模化离子交换法废水回收固体氯化铵装置，创新采用钛合金材料与三效蒸发工艺，初步 实现了高浓度含氨氮废水的资源化利用——由此，他们持续工艺研发，产生几十项专利技术，并先后投 入上亿元，不断升级建设回收系统，在行业内率先完成了离子交换法生产碳酸钾全物料循环利用及无工 艺废水排放。同时，他们对含氨氮废水的治理，不仅解决了环保问题，使原料利用率接近理论值，更将 副产物转化为优质产品，助力企业在行业中脱颖而出，真正实现了清洁生产的闭环。其"离子交换法低 温自碳化生产碳酸钾"项目，被列入国家火炬计划，其废水治理项目，被国家列为含氨氮废水高技术产 业化示范项目。另外，他们研发的高效热泵连续蒸发结晶系统，使能耗再降37%，他们自主优化M V R 1月24日，在清华大学召开的2025年度石油和化工行业十大新闻暨年度舆情报告发布会上， ...

证券日报网讯1月23日，大洋生物（003017）在互动平台回答投资者提问时表示，公司参股的浙江芯之 纯半导体材料有限公司主要业务是生产制造石墨基高纯陶瓷产品，可以应用于半导体设备以及LED等外 延设备的零部件方面。其技术优势在于拥有自主研发的核心生产设备及产品工艺配方，其生产的产品属 于第三代半导体碳化硅材料领域。 ...

2026 年 1 月 21 日，公司赎回上述理财产品，赎回本金 2,000.00 万元，分别 获得理财收益 24.10 万元及 24.58 万元，赎回的本金及理财收益已全额存入募集资 金专户。具体情况如下： 单位：万元 证券代码：003017 股票简称：大洋生物 公告编号：2026-005 浙江大洋生物科技集团股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回 并继续进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江大洋生物科技集团股份有限公司（以下简称"公司""本公司"或"大 洋生物"）于 2025 年 8 月 22 日召开第六届董事会第五次会议、第六届监事会第 五次会议，审议通过了《关于继续使用部分闲置募集资金进行现金管理的议案》。 根据《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》 等有关规定，为充分利用公司闲置募集资金，提高资金利用率，在不影响募投项 目建设使用的前提下，公司（含子公司福建舜跃科技股份有限公司，以下简称"福 建舜跃"）使用最高额度不超过 12,000.00 万元（含本数）闲置募集 ...

证券代码：003017 证券简称：大洋生物 公告编号：2026-004 浙江大洋生物科技集团股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 1、股东会届次：2026 年第一次临时股东会 特别提示： 2、股东会的召集人：公司董事会 1、本次股东会召开期间不存在增加、否决或变更提案的情形。 3、会议主持人：公司董事长陈阳贵先生 2、本次股东会采取现场投票表决和网络投票表决相结合的方式进行。 4、会议召开的合法、合规性：本次股东会会议的召集、召开程序符合《中 华人民共和国公司法》《上市公司股东会规则》和《浙江大洋生物科技集团股份 有限公司章程》的有关规定。 一、会议召开和出席情况 （2）网络投票时间：2026 年 1 月 9 日（星期五）。其中：通过深圳证券交 易所交易系统进行网络投票的具体时间为 2026 年 1 月 9 日（星期五）9:15—9:25、 9:30—11:30 和 13:00—15:00；通过深圳证券交易所互联网投票的具体时间为 2026 年 1 月 9 日（星期五）上午 9:15 至 2026 ...

上海市锦天城律师事务所 法律意见书 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 关于浙江大洋生物科技集团股份有限公司 2026 年第一次临时股东会的 上海市锦天城律师事务所 关于浙江大洋生物科技集团股份有限公司 2026 年第一次临时股东会的 法律意见书 致：浙江大洋生物科技集团股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江大洋生物科技集团股 份有限公司（以下简称"公司"）委托，就公司召开 2026 年第一次临时股东会（以 下简称"本次股东会"）的有关事宜，根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《上市公司股东会规则》等法律、法规、规章和其他规范性文 件以及《浙江大洋生物科技集团股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用 ...

Core Viewpoint - The potassium carbonate industry has transformed from a high-energy, high-pollution sector to a green and sustainable one, exemplified by Zhejiang Dayang Biotechnology Group Co., Ltd's journey over the past 50 years, showcasing its growth and adaptation in response to China's economic reforms and market demands [1][4]. Group 1: Company Evolution - Dayang Biotechnology has evolved from a small collective workshop in 1976 to a leading enterprise with products sold globally, marking significant milestones such as shareholding reform, listing on the Shenzhen Stock Exchange, and receiving multiple honors like "National Intellectual Property Advantage Enterprise" [1][4]. - The company anticipates a net profit increase of over 50% for the fiscal year 2025, driven by the growth of its core products, potassium carbonate and veterinary raw materials, indicating strong growth momentum [9][23]. Group 2: Technological Innovation - Dayang Biotechnology has prioritized technological innovation, achieving a three-stage evolution from survival to competitive advantage and future leadership, with significant advancements in production processes and environmental sustainability [11][13]. - The company developed a proprietary low-temperature carbonization technology for potassium carbonate production, which integrates environmental protection and cost efficiency, establishing a competitive edge in the market [13][15]. Group 3: Environmental Commitment - Dayang Biotechnology has invested nearly 100 million yuan in environmental initiatives, achieving zero wastewater discharge in inorganic product production, and transforming environmental compliance into a competitive asset [15][16]. - The company has pioneered technologies for treating low-concentration ammonium chloride wastewater, contributing to its zero discharge goal and creating new profit sources from recovered materials [15][16]. Group 4: Community Engagement - Over its 50-year history, Dayang Biotechnology has played a crucial role in local economic development, contributing significantly to tax revenues and community welfare, and demonstrating strong social responsibility [18][19]. - The company has actively participated in local governance and infrastructure projects, such as securing water sources for the community, showcasing its commitment to social engagement and environmental stewardship [19][21]. Group 5: Future Outlook - Dayang Biotechnology aims to leverage technological innovation and high-quality development to enhance its competitive position, with plans to invest in high-end materials like polyether ether ketone (PEEK) to meet national strategic needs [14][23]. - The company is positioned for sustainable growth, with a focus on maintaining its core business while exploring new high-value sectors, reflecting a balanced strategy of preservation and innovation [22][23].

Group 1 - The company announced the redemption of a large deposit certificate from Hangzhou Bank, amounting to 10 million yuan, on January 6, 2026, yielding a profit of 253,600 yuan [2] - On the same day, the company reinvested the idle raised funds of 10 million yuan into a similar two-year principal-protected floating income product, with an expected annualized return of 2.55% [2]

证券代码：003017 证券简称：大洋生物 公告编号：2026-003 浙江大洋生物科技集团股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回 并继续进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江大洋生物科技集团股份有限公司（以下简称"公司""本公司"或"大 洋生物"）于 2025 年 8 月 22 日召开第六届董事会第五次会议、第六届监事会第 五次会议，审议通过了《关于继续使用部分闲置募集资金进行现金管理的议案》。 根据《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》 等有关规定，为充分利用公司闲置募集资金，提高资金利用率，在不影响募投项 目建设使用的前提下，公司（含子公司福建舜跃科技股份有限公司，以下简称"福 建舜跃"）使用最高额度不超过 12,000.00 万元（含本数）闲置募集资金进行现金 管理（在此额度内可滚动使用），自董事会审议通过之日起 12 个月之内有效。具 体内容详见公司在《证券时报》《证券日报》和巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于继续使用 ...

Core Viewpoint - The company, Dayang Bio (003017.SZ), is expected to achieve significant growth in its annual net profit, driven by the dual benefits of increased volume and price in its core products, potassium carbonate and veterinary raw materials [2][4]. Financial Performance - The company forecasts a net profit attributable to shareholders of 96 million to 110 million yuan for the year, representing a year-on-year increase of 50.60% to 72.56% [2][4]. - The expected net profit excluding non-recurring items is projected to be between 90 million and 104 million yuan, with a year-on-year growth of 47.14% to 70.02% [2][4]. - In the first half of 2025, the potassium carbonate segment is anticipated to generate revenue of 349 million yuan, reflecting an 11.48% increase year-on-year, with a gross margin of 20.42%, up by 3.61 percentage points [4]. - The veterinary raw materials segment is expected to achieve revenue of approximately 91.62 million yuan in the first half of 2025, accounting for 18.35% of total revenue, marking a substantial year-on-year growth of 66.56% [5]. Research and Development - The company has committed to long-term R&D, with cumulative R&D expenses reaching 180 million yuan from 2020 to the third quarter of 2025 [6]. - R&D expenses have shown a steady increase over the years, with amounts of 22.33 million yuan, 27.84 million yuan, 34.06 million yuan, 39.22 million yuan, 28.78 million yuan, and 27.70 million yuan recorded [6]. - As of June 2025, the company holds 51 valid invention patents and 21 utility model patents, and has participated in drafting five national standards and three industry standards [6]. Strategic Expansion - The company plans to invest 500 million yuan in expanding its production capacity for potassium hydroxide and potassium carbonate, with a project completion date set for December 2025 [7]. - An additional investment of 193 million yuan is allocated for a project to produce 2,000 tons of specialty polymer materials, aiming to establish a closed-loop industrial chain [7]. - The company has also made significant progress in the semiconductor materials sector, with a 30% stake in a project that is nearing trial production, expected to commence in October 2025 [7].

Market Overview - As of January 5, the Shanghai Composite Index closed at 4023.42 points, with an increase of 1.38% [1] - The Shenzhen Component Index closed at 13828.63 points, up by 2.24% [1] - The ChiNext Index closed at 3294.55 points, rising by 2.85% [1] Trading Volume Analysis - A total of 2944 stocks saw an increase in average transaction volume, with 120 stocks experiencing a rise of over 50% [1] - 1627 stocks reported a decrease in average transaction volume [1] - Notable stocks with significant increases in transaction volume include Meihua Medical, Shengda Forestry, and Guanghua Co., Ltd. [1] Active Stocks by Transaction Volume - The stocks with the highest increase in average transaction volume include: - Meihua Medical: 20.00% increase, average transaction volume of 1815 shares, up by 407.72% [2] - Shengda Forestry: 10.05% increase, average transaction volume of 3127 shares, up by 185.31% [2] - Guanghua Co., Ltd.: 10.00% increase, average transaction volume of 768 shares, up by 185.24% [2] Active Stocks by Transaction Count - The stocks with the highest increase in transaction count include: - Tianchuang Fashion: 1.65% increase, 53725 transactions, up by 1815.33% [3] - *ST Yushun: -4.97% decrease, 5787 transactions, up by 1653.64% [3] - Hefei Urban Construction: 4.36% increase, 168503 transactions, up by 1330.05% [3] Stocks with Significant Increases in Both Volume and Count - Aipeng Medical: 20.00% increase, average transaction volume of 781 shares, up by 179.31%, with 24056 transactions, up by 81.27% [4] - Dayang Biological: 10.01% increase, average transaction volume of 623 shares, up by 164.36%, with 14388 transactions, up by 127.91% [5] - Maipu Medical: 20.00% increase, average transaction volume of 384 shares, up by 135.27%, with 9581 transactions, up by 315.66% [5]